ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	1.67T
Revenue (ttm)	278.64B
Net Income (ttm)	32.39B
Shares Out	20.15M
EPS (ttm)	1,689.86
PE Ratio	49.00
Forward PE	43.08
Dividend	500.00 (0.60%)
Ex-Dividend Date	Dec 27, 2024

Volume	159,567
Average Volume	190,374
Open	81,000
Previous Close	81,000
Day's Range	80,500 - 84,000
52-Week Range	62,900 - 120,800
Beta	0.56
RSI	43.92
Earnings Date	Jan 31, 2025

About ST Pharm

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2023, ST Pharm's revenue was 284.99 billion, an increase of 14.31% compared to the previous year's 249.32 billion. Earnings were 19.58 billion, an increase of 8.78%.